CompletedPhase 1NCT04715750

Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity

Studying Classic progressive supranuclear palsy syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Life Molecular Imaging GmbH
Principal Investigator
Andrew Stephens, MD, PhD
Life Molecular Imaging GmbH
Intervention
[18F]-PI2620(drug)
Enrollment
10 enrolled
Eligibility
50-80 years · All sexes
Timeline
20202022

Study locations (1)

Collaborators

Life Molecular Imaging SA

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04715750 on ClinicalTrials.gov

Other trials for Classic progressive supranuclear palsy syndrome

Additional recruiting or active studies for the same condition.

See all trials for Classic progressive supranuclear palsy syndrome

← Back to all trials